GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways

Metabolism: Clinical and Experimental

Volumn 62, Issue 9, 2013, Pages 1279-1286

  Aronis, Konstantinos N ^a,b   Chamberland, John P ^a   Mantzoros, Christos S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

Akt; Angiogenesis src; GLP 1; PKC

Indexed keywords

ANGIOGENESIS INHIBITOR; BISINDOLYLMALEIMIDE; GLUCAGON LIKE PEPTIDE 1; PROTEIN KINASE B INHIBITOR; SCAFFOLD PROTEIN; STEROID RECEPTOR COACTIVATOR 1;

ANGIOGENESIS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PHASE CONTRAST MICROSCOPE; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL;

5' ADENOSINE MONOPHOSPHATE (5'AMP) -ACTIVATED PROTEIN KINASE; AKT; AMPK; ANGIOGENESIS; ELISA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENOS; ENZYME LINKED IMMUNOSORBENT ASSAY; FAK; FLOW-MEDIATED DILATATION; FMD; FOCAL ADHESION KINASE; GLP-1; GLUCAGON-LIKE PEPTIDE 1; HCAECS; HUMAN CORONARY ARTERY ENDOTHELIAL CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUVECS; LEFT VENTRICULAR EJECTION FRACTION; LVEF; NITRIC OXIDE SYNTHASE; NOS; OD; OPTICAL DENSITY; PHOSPHATIDYLINOSITIDE 3-KINASE; PI3K; PKA; PKC; PROTEIN KINASE A; PROTEIN KINASE C; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3; SRC; STAT-3; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF;

CELLS, CULTURED; ENDOTHELIAL CELLS; GLUCAGON-LIKE PEPTIDE 1; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-AKT; SRC-FAMILY KINASES;

EID: 84883136496     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2013.04.010     Document Type: Article

References (49)

1. L.K. Phillips, and J.B. Prins Update on incretin hormones Ann N Y Acad Sci 1243 2011 E55 E74
2. D.C. Klonoff, J.B. Buse, L.L. Nielsen, X. Guan, C.L. Bowlus, and J.H. Holcombe Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years Curr Med Res Opin 24 2008 275 286
3. J. Cuthbertson, S. Patterson, F.P. O'Harte, and P.M. Bell Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus Metabolism 60 2011 52 56
4. L.A. Nikolaidis, S. Mankad, G.G. Sokos, G. Miske, A. Shah, and D. Elahi Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 2004 962 965
5. G.G. Sokos, L.A. Nikolaidis, S. Mankad, D. Elahi, and R.P. Shannon Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure J Card Fail 12 2006 694 699
6. C. Irace, S. De Luca, E. Shehaj, C. Carallo, A. Loprete, and F. Scavelli Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research Diab Vasc Dis Res 10 2013 72 77
7. S. Herzlinger, and E.S. Horton Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes Diabetes Res Clin Pract 100 1 2013 1 10
8. T. Forst, G. Michelson, F. Ratter, M.M. Weber, S. Anders, and M. Mitry Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function Diabet Med 29 2012 1115 1118
9. B. Schisano, A.L. Harte, K. Lois, P. Saravanan, N. Al-Daghri, and O. Al-Attas GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress Regul Pept 174 2012 46 52
10. M. Terasaki, M. Nagashima, T. Watanabe, K. Nohtomi, Y. Mori, and A. Miyazaki Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice Metabolism 61 2012 974 977
11. O. Erdogdu, D. Nathanson, A. Sjoholm, T. Nystrom, and Q. Zhang Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor Mol Cell Endocrinol 325 2010 26 35
12. C.Y. Huang, C.M. Shih, N.W. Tsao, Y.W. Lin, P.H. Huang, and S.C. Wu Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells Br J Pharmacol 167 2012 1506 1519
13. Z.K. Otrock, R.A. Mahfouz, J.A. Makarem, and A.I. Shamseddine Understanding the biology of angiogenesis: review of the most important molecular mechanisms Blood Cells Mol Dis 39 2007 212 220
14. J.T. Durham, and I.M. Herman Microvascular modifications in diabetic retinopathy Curr Diab Rep 11 2011 253 264
15. T.N. Crawford, D.V. Alfaro 3rd, J.B. Kerrison, and E.P. Jablon Diabetic retinopathy and angiogenesis Curr Diabetes Rev 5 2009 8 13
16. J. Folkman Role of angiogenesis in tumor growth and metastasis Semin Oncol 29 2002 15 18
17. M.A. Cabrita, L.M. Jones, J.L. Quizi, L.A. Sabourin, B.C. McKay, and C.L. Addison Focal adhesion kinase inhibitors are potent anti-angiogenic agents Mol Oncol 5 2011 517 526
18. C. Herrmann, R. Goke, G. Richter, H.C. Fehmann, R. Arnold, and B. Goke Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients Digestion 56 1995 117 126
19. T. Vilsboll, H. Agerso, T. Krarup, and J.J. Holst Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects J Clin Endocrinol Metab 88 2003 220 224
20. VA pharmacy benefits management services MAP, and VISN pharmacist executives 2010 Liraglutide (Victoza®) National PBM Drug Monograph. In: http://www.pbm.va.gov/PBM/clinicalguidance/drugmonographs/Liraglutidemonograph. pdf ed.
21. D.G. Parkes, R. Pittner, C. Jodka, P. Smith, and A. Young Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro Metabolism 50 2001 583 589
22. R. Marfella, F.C. Sasso, M.R. Rizzo, P. Paolisso, M. Barbieri, and V. Padovano Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes Exp Diabetes Res 2012 2012 892706
23. S. Dimmeler, and A.M. Zeiher Akt takes center stage in angiogenesis signaling Circ Res 86 2000 4 5
24. M.E. Davis, H. Cai, L. McCann, T. Fukai, and D.G. Harrison Role of c-Src in regulation of endothelial nitric oxide synthase expression during exercise training Am J Physiol Heart Circ Physiol 284 2003 H1449 H1453
25. M. Marx, S.L. Warren, and J.A. Madri pp 60(c-src) modulates microvascular endothelial phenotype and in vitro angiogenesis Exp Mol Pathol 70 2001 201 213
26. J. Schlessinger New roles for Src kinases in control of cell survival and angiogenesis Cell 100 2000 293 296
27. B.P. Eliceiri, R. Paul, P.L. Schwartzberg, J.D. Hood, J. Leng, and D.A. Cheresh Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability Mol Cell 4 1999 915 924
28. T. Murohara, T. Asahara, M. Silver, C. Bauters, H. Masuda, and C. Kalka Nitric oxide synthase modulates angiogenesis in response to tissue ischemia J Clin Invest 101 1998 2567 2578
29. S.C. Bir, Y. Xiong, C.G. Kevil, and J. Luo Emerging role of PKA/eNOS pathway in therapeutic angiogenesis for ischaemic tissue diseases Cardiovasc Res 95 2012 7 18
30. D. Fukumura, T. Gohongi, A. Kadambi, Y. Izumi, J. Ang, and C.O. Yun Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability Proc Natl Acad Sci U S A 98 2001 2604 2609
31. A. Dei Cas, and L. Gnudi VEGF and angiopoietins in diabetic glomerulopathy: how far for a new treatment? Metabolism 61 2012 1666 1673
32. H. Xu, P. Czerwinski, M. Hortmann, H.Y. Sohn, U. Forstermann, and H. Li Protein kinase C alpha promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor Cardiovasc Res 78 2008 349 355
33. K. Ban, M.H. Noyan-Ashraf, J. Hoefer, S.S. Bolz, D.J. Drucker, and M. Husain Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 117 2008 2340 2350
34. M.H. Noyan-Ashraf, M.A. Momen, K. Ban, A.M. Sadi, Y.Q. Zhou, and A.M. Riazi GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice Diabetes 58 2009 975 983
35. A.K. Bose, M.M. Mocanu, R.D. Carr, C.L. Brand, and D.M. Yellon Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury Diabetes 54 2005 146 151
36. J.H. Best, B.J. Hoogwerf, W.H. Herman, E.M. Pelletier, D.B. Smith, and M. Wenten Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database Diabetes Care 34 2011 90 95
37. S.J. Hamilton, G.T. Chew, T.M. Davis, and G.F. Watts Prevalence and predictors of abnormal arterial function in statin-treated type 2 diabetes mellitus patients Metabolism 61 2012 349 357
38. B.G. Seligman, C.A. Polanczyk, A.S. Santos, M. Foppa, M. Junges, and L. Bonzanini Intensive practical lifestyle intervention improves endothelial function in metabolic syndrome independent of weight loss: a randomized controlled trial Metabolism 60 2011 1736 1740
39. T. Nystrom, M.K. Gutniak, Q. Zhang, F. Zhang, J.J. Holst, and B. Ahren Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease Am J Physiol Endocrinol Metab 287 2004 E1209 E1215
40. Y. Ishibashi, Y. Nishino, T. Matsui, M. Takeuchi, and S. Yamagishi Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level Metabolism 60 2011 1271 1277
41. H. Hendarto, T. Inoguchi, Y. Maeda, N. Ikeda, J. Zheng, and R. Takei GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases Metabolism 61 2012 1422 1434
42. H.W. Wang, M. Mizuta, Y. Saitoh, K. Noma, H. Ueno, and M. Nakazato Glucagon-like peptide-1 and candesartan additively improve glucolipotoxicity in pancreatic beta-cells Metabolism 60 2011 1081 1089
43. K. Chen, X. Yu, K. Murao, H. Imachi, J. Li, and T. Muraoka Exendin-4 regulates GLUT2 expression via the CaMKK/CaMKIV pathway in a pancreatic beta-cell line Metabolism 60 2011 579 585
44. G. Pacini, K. Thomaseth, and B. Ahren Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice Metabolism 59 2010 988 992
45. C. Guidone, M. Manco, E. Valera-Mora, A. Iaconelli, D. Gniuli, and A. Mari Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery Diabetes 55 2006 2025 2031
46. E. Naslund, P. Gryback, P.M. Hellstrom, H. Jacobsson, J.J. Holst, and E. Theodorsson Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity Int J Obes Relat Metab Disord 21 1997 387 392
47. V. Ionut, and R.N. Bergman Mechanisms responsible for excess weight loss after bariatric surgery J Diabetes Sci Technol 5 2011 1263 1282
48. A.D. Strader, T.P. Vahl, R.J. Jandacek, S.C. Woods, D.A. D'Alessio, and R.J. Seeley Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats Am J Physiol Endocrinol Metab 288 2005 E447 E453
49. H. Kakizawa, M. Itoh, Y. Itoh, S. Imamura, Y. Ishiwata, and T. Matsumoto The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients Metabolism 53 2004 550 555